Role of tetrabenazine for Huntington's disease-associated chorea

Annals of Pharmacotherapy

Volumn 44, Issue 6, 2010, Pages 1080-1089

  Poon, Linda H ^a,b,c   Kang, Gail A ^a,c   Lee, Audrey J ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF THE PACIFIC   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chorea; Huntington's disease; Tetrabenazine

Indexed keywords

CYTOCHROME P450 2D6; TETRABENAZINE;

ASTHENIA; CLINICAL TRIAL; DEPRESSION; DROWSINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; HUNTINGTON CHOREA; HYPERPROLACTINEMIA; MENTAL DISEASE; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SEDATION; SIDE EFFECT; SUICIDAL BEHAVIOR;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; HUNTINGTON DISEASE; PARKINSONIAN DISORDERS; SLEEP STAGES; TETRABENAZINE;

EID: 77952899450     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M582     Document Type: Review

References (54)

1. Walker FO. Huntington's disease. Semin Neurol 2007;27:143-150
2. Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Exp Rev Neurother 2006;6:7-17.
3. Huntington's Disease Society of America. Lifting the veil of Huntington's disease recommendations to the field from the Huntington's disease peer workshop. www.hdsa.org/images/content/1/1/11709.pdf (accessed 2009 Aug 31).
4. Setter SM, Neumiller JJ, Dobbins EK, et al. Treatment of chorea associated with Huntington's disease: focus on tetrabenazine. Consult Pharm 2009;24:524-537
5. National Institute of Neurological Disorders and Stroke. NNDS chorea information page. http://www.ninds.nih.gov/disorders/chorea/chorea.htm (accessed 2009 Sept 1).
6. Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord 2008;23:1491-1504
7. Kirkwood SC, Su JL, Conneally PM, Foroud T. Progression of symptoms in the early and middle stages of Huntington's disease. Arch Neurol 2001;58:273-278 (Pubitemid 32163165)
8. Product information. Xenazine (tetrabenazine). Deerfield, IL: Lundbeck Inc., July 2009.
9. Penney JB Jr, Young AB. Speculations on the functional anatomy of basal ganglia disorders. Annu Rev Neurosci 1983;6:73-94. (Pubitemid 13101459)
10. Chevalier G, Deniau JM. Disinhibition as a basic process in the expression of striatal functions. Trends Neurosci 1990;13:277-280 (Pubitemid 20193458)
11. Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990;12:244-254
12. Penney JB Jr, Young AB. Striatal inhomogeneities and basal ganglia function. Mov Disord 1986;1:3-15.
13. Deng YP, Albin RL, Penney JB, Young AB, Anderson KD, Reiner A. Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J Chem Neuroanat 2004;27:143-164 (Pubitemid 38739355)
14. Klockgether T, Dichgans J. Do neuroleptic drugs still have a place in neurological therapy? J Neurol 1990;237:221-225
15. Login IS, Cronin MJ, MacLeod RM. Tetrabenazine has properties of a dopamine receptor antagonist. Ann Neurol 1982;12:257-262 (Pubitemid 12053032)
16. Pettibone DJ, Totaro JA, Pflueger AB. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur J Pharmacol 1984;102:425-430 (Pubitemid 14064081)
17. Tomlinson DR. The mode of action of tetrabenazine on peripheral noradrenergic nerves. Br J Pharmacol 1977;61:339-344 (Pubitemid 8209161)
18. Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther 1959;127:103-109
19. Schreiber W, Krieg JC, Eichhorn T. Reversal of tetrabenazine induced depression by selective noradrenanline (norepinephrine) reuptake inhibition (letter). J Neurol Neurosurg Psychiatry 1999;67:550. (Pubitemid 29438220)
20. Scherman D. Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. J Neurochem 1986;47:331-339 (Pubitemid 16052845)
21. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 1982;11:41-47 (Pubitemid 12209517)
22. Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Adv Neurol 1983;37:277-289
23. Reches A, Burke RE, Kuhn CM, Hassan MN, Jackson VR, Fahn S. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther 1983;225:515-521 (Pubitemid 13070863)
24. Marshall FJ, Fahn S, Clarence-Smith K. Tetrabenazine as antichorea therapy in Huntington's disease: a randomized controlled trial used in clinical practice (letter). Neurology 2007;68:797.
25. Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord 2007;22:10-13 (Pubitemid 46382667)
26. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease. Neurology 2006;66:366-372
27. Frank S, Ondo W, Fahn S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 2008;31: 127-133 (Pubitemid 351787108)
28. Mehvar R, Jamali F, Watson MW, Skelton D. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. Drug Metab Dispos 1987;15:250-255
29. Astin KJ, Gumpert EW. Letter: tetrabenazine in chorea (letter). Lancet 1974;1:512.
30. Huang CY, McLeod JG. Holland RT, Elliot C. Tetrabenazine in the treatment of Huntington's chorea. Med J Aust 1976;1:583-584
31. McArthur AW, Pollock M, Smidt NA. Combined therapy with tetrabenazine and pimozide in Huntington's chorea: pilot study. N Z Med J 1976;82:114-116
32. Swash M, Roberts AH, Zakko H, Heathfield KW. Treatment of involuntary movement disorders with tetrabenazine. J Neurol Neurosurg Psychiatry 1972;35:186-191
33. McLellan DL. The suppression of involuntary movements with tetrabenazine. Scott Med J 1972;17:367-370
34. Toglia JU, McGlamery M, Sambandham RR. Tetrabenazine in the treatment of Huntington's chorea and other hyperkinetic movement disorders. J Clin Psychiatry 1978;39:81-87
35. Asher SW, Aminoff MJ. Tetrabenazine and movement disorders. Neurology 1981;31:1051-1054
36. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-362 (Pubitemid 27087603)
37. Paleacu D, Giladi N, Moore O, Stern A, Honigman S, Badarny S. Tetrabenazine treatment in movement disorders. Clin Neuropharmacol 2004; 27:230-233
38. Fasano A, Cadeddu F, Guidubaldi A, et al. The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol 2008;31:313-318
39. Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol 2002;25: 300-302 (Pubitemid 36025267)
40. Brusa L, Orlacchio A, Moschella V, Iani C, Bernardi G, Mercuri NB. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009;24:126-129
41. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 1996;11:136-142 (Pubitemid 26082779)
42. Munetz MR, Benjamin S. How to examine patients using the abnormal involuntary movement scale. Hosp Commun Psychiatry 1988;39:1172-1177
43. Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology 1981;31:1022-1026 (Pubitemid 11061744)
44. Petzinger GM, Bressman SB. A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment. Mov Disord 1997;12:246-248 (Pubitemid 27152033)
45. Ossemann M, Sindic CJ, Laterre C. Tetrabenazine as a cause of neuroleptic malignant syndrome (letter). Mov Disord 1996;11:95.
46. Stevens E, Roman A, Houa M, Razavi D, Jaspar N. Severe hypothermia during tetrabenazine therapy for tardive dyskinesia. Intensive Care Med 1998;24:369-371 (Pubitemid 28203889)
47. Snaith RP, Warren HD. Letter: treatment of Huntington's chorea with tetrabenazine. Lancet 1974;1:413-414
48. Burke RE, Reches A, Traub MM, Ilson J, Swash M, Fahn S. Tetrabenazine induces acute dystonic reactions. Ann Neurol 1985;17:200-202 (Pubitemid 15170444)
49. Kenney C, Hunter C, Mejia N, Jankovic J. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol 2006; 29:259-264
50. Tetrabenazine. Drug Facts & Comparisons 4.0. 2009. Available from Wolters Kluwer Health, Inc. http://online.factsandcomparisons.com/MonoDisp.aspx? monoID=fandchcp15253&quick=712810%7c21& search=712810%7c21&isstemmed = true (accessed 2009 Sept 23).
51. Paleacu D. Tetrabenazine in the treatment of Huntington's disease. Neuropsychiatr Dis Treat 2007;3:545-551
52. Jain S, Greene PE, Frucht SJ. Tetrabenazine therapy of pediatric hyperkinetic movement disorders. Mov Disord 2006;21:1966-1972 (Pubitemid 44848947)
53. Xenazine. Thomson PDR. Red Book for Windows version 61127, vol 56, expires 2010 Aug 31. July 2009 (Quarterly Release). Vol. 53 (accessed 2009 Jul 23).
54. Abilify. Thomson PDR. Red Book for Windows version 61127, vol 56, expires 2010 Aug 31. July 2009 (Quarterly Release). Vol. 53 (accessed 2009 Jul 23).